181 results
6-K
EX-99.3
BLRX
Bioline Rx Ltd
28 May 24
BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate
7:11am
. We primarily use external service providers to manufacture our therapeutic candidates for clinical trials and for the majority of our preclinical
6-K
EX-10.1
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
for such purpose, by a majority of the non-employee members of the Board of Directors or a majority of the members of a committee of non-employee directors … ) or to extend the term of such securities, and (c) securities issued pursuant to acquisitions or strategic transactions approved by a majority
6-K
EX-10.2
BLRX
Bioline Rx Ltd
1 Apr 24
BioLineRx Announces $6 Million Registered Direct Offering
10:35am
Ordinary Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding ADSs and underlying … to the identity of a majority of the board of directors of the Company.
(h) “Closing Bid Price” and “Closing Sale Price” means, for any security as of any
424B5
BLRX
Bioline Rx Ltd
1 Apr 24
Prospectus supplement for primary offering
10:30am
of our key employees, the majority of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions … of Directors
Our ordinary shares do not have cumulative voting rights in the election of directors. As a result, the holders of a majority of the voting
20-F/A
2023 FY
BLRX
Bioline Rx Ltd
26 Mar 24
Annual report (foreign) (amended)
4:57pm
, the majority of our officers and directors are residents of Israel. Accordingly, political, economic and military conditions in Israel … the date that the shareholders of both merging companies approved the merger. In addition, a majority of each class of securities of the target
20-F/A
EX-2.1
un2ii25sdu4g9rv0q
26 Mar 24
Annual report (foreign) (amended)
4:57pm
F-3
wx9hv6
29 Dec 23
Shelf registration (foreign)
4:15pm
6-K
EX-99
4t1 gnpjr2yyb79ibi
20 Nov 23
BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate
7:03am
6-K
EX-99
pf2pxtq
11 Sep 23
BioLineRx Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple
7:07am
6-K
EX-99
f2biy8p
30 Aug 23
BioLineRx Reports Second Quarter 2023 Financial Results and Recent Corporate
7:15am
6-K
EX-99
sy5 4grtylewx
30 Aug 23
Current report (foreign)
6:45am
6-K
46hlyqum2nnuz4hr7ec1
8 Aug 23
Current report (foreign)
5:25pm
6-K
EX-99
ua8l6
23 Jun 23
Notice of Annual General Meeting of Shareholders
4:16pm
6-K
EX-99
yxqsc04vnh0vijsu5
24 May 23
BioLineRx Reports First Quarter 2023 Financial Results and Recent Corporate
7:06am
6-K
EX-99
kq8z5yg5x1x0tt
17 Apr 23
BioLineRx Announces Publication in Nature Medicine of its GENESIS Phase 3 Clinical Trial Data Evaluating
11:08am
6-K
EX-99
z8iq c1ov180eaw46m
15 Nov 22
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate
7:07am
6-K
EX-99
fae0 tf1vatzul
10 Nov 22
Current report (foreign)
7:08am